Caidya
屏蔽该公司
取消屏蔽

制药· 1000-2000人

缔脉生物医药科技(上海)有限公司是一家临床合同研究组织(CRO),旨在为中国及全球生物医药公司和医疗器械公司提供高水准全方位的服务,包括为客户就临床开发的各个方面及产品注册申报出谋划策,也提供与临床试验相关的各种支持。致力于提高研发产品的成功率。 dMed Biopharmaceutical Company Limited is a clinical Contract Research Organization (CRO), providing high-end services to innovative biopharmaceutical and medical device companies. dMed is committed to increasing the probability of success of R&D products. Its services include Consulting, Clinical Operations, Biostatistics & Programming, Data Management, Pharmacovigilance, Clinical Science & Medical Affairs, Quality Assurance, Regulatory Affairs & Strategy. 我们的团队Our Team • 团队管理成员全部来自全球一流生物医药企业,或跨国临床研究外包服务企业的高级管理人员 From executive and management team of global ******* biopharmaceutical companies or multinational Contract Research Organizations •在各期临床试验及各类疾病领域拥有广泛经验,熟悉中国,美国,欧盟,日本等各地临床试验法规 Expertise in various therapeutic areas and all phases of clinical trials, familiar with clinical trial regulations in China, US, EU, Japan and other markets • 拥有高度责任感为客户服务,值得信赖的专业团队 Trustworthy and Professional team with strong sense of accountability to serve our clients 服务对象及主营业务Our Clients and Services • Provide service for domestic biopharmaceutical and medical device companies and small and medium-sized biopharmaceutical and medical device companies interested in China market End-to-End Services including Clinical Trial design and conduct, clinical trial data Analysis and Report, Regulatory submission, Systems support, Functional Services, comprehensive Consultation Services • Provide service for multinational biopharmaceutical and medical device companies (In China for China & In China for Global), such as Statistics, Data Management, Programming, Medical Writing, Pharmacovigilance and Risk Management, Regulatory documentation support and operations, Quality Assurance & Audit 热招职位Hot Job • 统计分析员/经理 • 数据管理专员/医学编码员/临床系统开发员 • 临床研究助理/项目经理 • 药物安全专员/经理 • 医学撰写专员/经理 • 质量保证专员/经理 • 药政事务专员/经理 详情请见公司官网:******************
...
查看全部 收起

资质认证

融资情况
012025
D轮 1.65亿美元
投资机构: 未公开
072021
C+轮 5000万美元
投资机构: Rock Springs Capital / 启峰资本
042021
战略合并 未披露
投资机构: 未公开
122020
C轮 1.00亿美元
投资机构: 启明创投 / 富达国际 / 易方达基金 / 礼来亚洲基金 / 红杉中国
102019
B轮 5000.00万美元
投资机构: 君联资本 / 启明创投 / 礼来亚洲基金
112016
A轮 5500.00万人民币
投资机构: 启明创投 / 泰睿投资
  
融资时间线